Avance Clinical, the largest full-service contract research organization (CRO) based in Australia, is emphasizing its extensive experience in early phase clinical trials as it prepares for BIO-Europe in Vienna, taking place from November 3 to 5, 2025. With over 30 years of expertise, the company is showcasing its Early Phase Center of Excellence, aiming to support European biotechs seeking to expedite their research and development processes.
Given the increasing pressures from investors and regulatory bodies, European biotechnology companies are increasingly looking towards Avance Clinical“s established pathways in Australia to facilitate their first-in-human (FIH) and early proof-of-concept studies. The advantages offered include rapid startup timelines, with approvals achievable in as little as 5 to 6 weeks thanks to Australia”s streamlined regulatory processes and Avance”s in-depth expertise in early phase trials.
“EU biotechs are often surprised to learn just how efficient Australia is for early phase research,” said Mark Harvill, CEO of Avance Clinical. “Our new Early Phase Center of Excellence for Biotechs underlines our dedication to maintaining scientific integrity and innovation while helping sponsors meet crucial milestones more rapidly and without compromising on quality.”
Having guided more than 710 emerging biotechs across over 250 therapeutic indications, Avance Clinical boasts a robust in-house team with expertise in scientific and regulatory affairs, complemented by top-tier clinical operations. Their dedicated center was specifically established to cater to the demands of international sponsors navigating the complexities of FIH and early development studies.
“In the face of rising competition within the biotech sector, speed and quality during early development phases are vital,” stated Ben Edwards, Chief Operating Officer of Avance Clinical. “By leveraging the Australian Advantage—which includes a potential R&D tax rebate of up to 43.5%—alongside our extensive early phase knowledge, EU sponsors can reduce risks associated with their programs and maintain financial efficiency while progressing swiftly to global markets.”
European biotechs attending BIO-Europe 2025 are encouraged to connect with Avance Clinical representatives, including Liahna Toy, Vice President of Commercial Business Development, and Dewald Jacobs, Director of Business Development, at Booth C185 in the Vienna Congress & Convention Center. This event presents a valuable opportunity for EU sponsors to explore how Avance Clinical”s early phase expertise and the Australian Advantage can significantly enhance their development pipelines.
About Avance Clinical
Avance Clinical is recognized as the largest premium full-service CRO headquartered in Australia, conducting high-quality clinical trials across Australia, New Zealand, Asia, North America, and Europe for international biotech firms. The organization has received multiple accolades, including Frost & Sullivan”s CRO Market Leadership and Customer Value Leadership Awards. With over three decades of experience and a broad therapeutic portfolio covering more than 250 indications, Avance Clinical offers services ranging from pre-clinical to late-phase trials, supported by exceptional regulatory, clinical, and operational teams.
For more information, visit www.avancecro.com to submit a request for proposal and discover further details about the Australian Advantage and the Early Phase Center of Excellence.
Contact:
Gabe Martinez
Director, Content, Media, & PR
308-237-5567
[email protected]
A photo accompanying this announcement is available at: link
